Histogenics Corporation (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

Several other research analysts also recently commented on the company. ValuEngine upgraded Histogenics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. HC Wainwright set a $4.00 price objective on Histogenics Corporation and gave the stock a “buy” rating in a report on Friday, August 11th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $4.00 price objective on shares of Histogenics Corporation in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $5.25.

Shares of Histogenics Corporation (NASDAQ:HSGX) opened at 1.92 on Friday. The company’s market cap is $43.18 million. Histogenics Corporation has a 52-week low of $1.45 and a 52-week high of $3.75. The firm has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.75.

Histogenics Corporation (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.06. During the same period in the previous year, the company posted ($0.61) earnings per share. Equities research analysts anticipate that Histogenics Corporation will post ($1.09) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Histogenics Corporation (HSGX) Lowered to Hold at Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/09/histogenics-corporation-hsgx-lowered-to-hold-at-zacks-investment-research.html.

A hedge fund recently raised its stake in Histogenics Corporation stock. Sabby Management LLC boosted its holdings in shares of Histogenics Corporation (NASDAQ:HSGX) by 15.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,095,422 shares of the biotechnology company’s stock after purchasing an additional 150,531 shares during the period. Sabby Management LLC owned about 5.31% of Histogenics Corporation worth $1,895,000 at the end of the most recent reporting period. 50.08% of the stock is currently owned by hedge funds and other institutional investors.

About Histogenics Corporation

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get a free copy of the Zacks research report on Histogenics Corporation (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.